RESUMEN
BACKGROUND: Mucopolysaccharidosis (MPS) and glycoproteinosis are 2 groups of heterogenous lysosomal storage disorders (LSDs) caused by defective degradation of glycosaminoglycans (GAGs) and glycoproteins, respectively. Oligosaccharides and glycoamino acids have been recognized as biomarkers for MPS and glycoproteinosis. Given that both groups of LSDs have overlapping clinical features, a multiplexed assay capable of unambiguous subtyping is desired for accurate diagnosis, and potentially for severity stratification and treatment monitoring. METHODS: Urinary oligosaccharides were derivatized with 3-methyl-1-phenyl-2-pyrazoline-5-one (PMP) and analyzed by ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) together with the underivatized glycoamino acids. Novel biomarkers were identified with a semi-targeted approach with precursor mass scanning, the fragmentation pattern (if applicable), and the biochemical basis of the condition. RESULTS: A UPLC-MS/MS analysis with improved chromatographic separation was developed. Novel biomarkers for MPS-IIIA, IIIB, IIIC, and VII were identified and validated. A total of 28 oligosaccharides, 2 glycoamino acids, and 2 ratios were selected as key diagnostic biomarkers. Validation studies including linearity, lower limit of quantitation (LLOQ), and precision were carried out with the assay performance meeting the required criteria. Age-specific reference ranges were collected. In the 76 untreated patients, unambiguous diagnosis was achieved with 100% sensitivity and specificity. Additionally, the levels of disease-specific biomarkers were substantially reduced in the treated patients. CONCLUSIONS: A multiplexed UPLC-MS/MS assay for urinary oligosaccharides and glycoamino acids measurement was developed and validated. The assay is suitable for the accurate diagnosis and subtyping of MPS and glycoproteinosis, and potentially for severity stratification and monitoring response to treatment.
Asunto(s)
Biomarcadores , Glicoproteínas , Mucopolisacaridosis , Oligosacáridos , Espectrometría de Masas en Tándem , Humanos , Espectrometría de Masas en Tándem/métodos , Oligosacáridos/orina , Niño , Cromatografía Líquida de Alta Presión/métodos , Preescolar , Biomarcadores/orina , Mucopolisacaridosis/orina , Mucopolisacaridosis/diagnóstico , Adolescente , Glicoproteínas/orina , Lactante , Masculino , Femenino , Adulto , Aminoácidos/orina , Adulto JovenRESUMEN
GM2 gangliosidosis is a group of rare lysosomal storage disorders (LSDs) including Tay-Sachs disease (TSD) and Sandhoff disease (SD), caused by deficiency in activity of either ß-hexosaminidase A (HexA) or both ß-hexosaminidase A and ß-hexosaminidase B (HexB). Methods for screening and diagnosis of TSD and SD include measurement and comparison of the activity of these two enzymes. Here we report a novel method for duplex screening of dried blood spots (DBS) for TSD and SD by liquid chromatography-tandem mass spectrometry (LC-MS/MS). The method requires incubation of a single 3 mm DBS punch with the assay cocktail followed by the injection into the LC-MS/MS. The performance of the method was evaluated by comparing the confirmed TSD and SD patient DBS to random healthy newborn DBS which showed easy discrimination between the three cohorts. The method is multiplexable with other LSD MS/MS enzyme assays which is critical to the continued expansion of the NBS panels.
Asunto(s)
Pruebas con Sangre Seca , Tamizaje Neonatal , Enfermedad de Sandhoff , Espectrometría de Masas en Tándem , Enfermedad de Tay-Sachs , Humanos , Enfermedad de Tay-Sachs/diagnóstico , Enfermedad de Tay-Sachs/sangre , Enfermedad de Tay-Sachs/enzimología , Recién Nacido , Espectrometría de Masas en Tándem/métodos , Tamizaje Neonatal/métodos , Pruebas con Sangre Seca/métodos , Enfermedad de Sandhoff/diagnóstico , Enfermedad de Sandhoff/sangre , Cromatografía Liquida/métodos , Pruebas de Enzimas/métodos , Cadena alfa de beta-Hexosaminidasa/sangre , Hexosaminidasa A/sangre , Hexosaminidasa B/sangreRESUMEN
[This corrects the article DOI: 10.1016/j.ymgmr.2021.100744.].